TY - JOUR
T1 - The Heart Failure Association Atlas
T2 - Heart Failure Epidemiology and Management Statistics 2019
AU - in collaboration with the National Heart Failure Societies of the ESC member countries (see Appendix)
AU - Seferović, Petar M.
AU - Vardas, Panagiotis
AU - Jankowska, Ewa A.
AU - Maggioni, Aldo P.
AU - Timmis, Adam
AU - Milinković, Ivan
AU - Polovina, Marija
AU - Gale, Chris P.
AU - Lund, Lars H.
AU - Lopatin, Yuri
AU - Lainscak, Mitja
AU - Savarese, Gianluigi
AU - Huculeci, Radu
AU - Kazakiewicz, Dzianis
AU - Coats, Andrew J.S.
AU - Berger, Rudolf
AU - Jahangirov, Tofiq
AU - Kurlianskaya, Alena
AU - Troisfontaines, Pierre
AU - Droogne, Walter
AU - Hudic, Larisa Dizdarevic
AU - Tokmakova, Mariya
AU - Glavaš, Duška
AU - Barberis, Vassilis
AU - Spinar, Jindrich
AU - Wolsk, Emil
AU - Uuetoa, Tiina
AU - Tolppanen, Heli
AU - Kipiani, Zviad
AU - Störk, Stefan
AU - Bauersachs, Johann
AU - Keramida, Kalliopi
AU - Parissis, John
AU - Habon, Tamas
AU - Gotsman, Israel
AU - Weinstein, Jean Marc
AU - Ingimarsdottir, Inga Jona
AU - Crowley, Jim
AU - Dalton, Barbra
AU - Aspromonte, Nadia
AU - Nodari, Savina
AU - Volterrani, Maurizio
AU - Rakisheva, Amina
AU - Mirrakhimov, Erkin
AU - Kamzola, Ginta
AU - Skouri, Hadi
AU - Celutkiene, Jelena
AU - Jovanova, Silvana
AU - Vataman, Eleonora
AU - Cobac, Irina Pogorevici
N1 - Publisher Copyright:
© 2021 European Society of Cardiology
PY - 2021/6
Y1 - 2021/6
N2 - Aims: The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) developed the HFA Atlas to provide a contemporary description of heart failure (HF) epidemiology, resources, reimbursement of guideline-directed medical therapy (GDMT) and activities of the National Heart Failure Societies (NHFS) in ESC member countries. Methods and results: The HFA Atlas survey was conducted in 2018–2019 in 42 ESC countries. The quality and completeness of source data varied across countries. The median incidence of HF was 3.20 [interquartile range (IQR) 2.66–4.17] cases per 1000 person-years, ranging from ≤2 in Italy and Denmark to >6 in Germany. The median HF prevalence was 17.20 (IQR 14.30–21) cases per 1000 people, ranging from ≤12 in Greece and Spain to >30 in Lithuania and Germany. The median number of HF hospitalizations was 2671 (IQR 1771–4317) per million people annually, ranging from <1000 in Latvia and North Macedonia to >6000 in Romania, Germany and Norway. The median length of hospital stay for an admission with HF was 8.50 (IQR 7.38–10) days. Diagnostic and management resources for HF varied, with high-income ESC member countries having substantially more resources compared with middle-income countries. The median number of hospitals with dedicated HF centres was 1.16 (IQR 0.51–2.97) per million people, ranging from <0.10 in Russian Federation and Ukraine to >7 in Norway and Italy. Nearly all countries reported full or partial reimbursement of standard GDMT, except ivabradine and sacubitril/valsartan. Almost all countries reported having NHFS or working groups and nearly half had HF patient organizations. Conclusions: The first report from the HFA Atlas has shown considerable heterogeneity in HF disease burden, the resources available for its management and data quality across ESC member countries. The findings emphasize the need for a systematic approach to the capture of HF statistics so that inequalities and improvements in care may be quantified and addressed.
AB - Aims: The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) developed the HFA Atlas to provide a contemporary description of heart failure (HF) epidemiology, resources, reimbursement of guideline-directed medical therapy (GDMT) and activities of the National Heart Failure Societies (NHFS) in ESC member countries. Methods and results: The HFA Atlas survey was conducted in 2018–2019 in 42 ESC countries. The quality and completeness of source data varied across countries. The median incidence of HF was 3.20 [interquartile range (IQR) 2.66–4.17] cases per 1000 person-years, ranging from ≤2 in Italy and Denmark to >6 in Germany. The median HF prevalence was 17.20 (IQR 14.30–21) cases per 1000 people, ranging from ≤12 in Greece and Spain to >30 in Lithuania and Germany. The median number of HF hospitalizations was 2671 (IQR 1771–4317) per million people annually, ranging from <1000 in Latvia and North Macedonia to >6000 in Romania, Germany and Norway. The median length of hospital stay for an admission with HF was 8.50 (IQR 7.38–10) days. Diagnostic and management resources for HF varied, with high-income ESC member countries having substantially more resources compared with middle-income countries. The median number of hospitals with dedicated HF centres was 1.16 (IQR 0.51–2.97) per million people, ranging from <0.10 in Russian Federation and Ukraine to >7 in Norway and Italy. Nearly all countries reported full or partial reimbursement of standard GDMT, except ivabradine and sacubitril/valsartan. Almost all countries reported having NHFS or working groups and nearly half had HF patient organizations. Conclusions: The first report from the HFA Atlas has shown considerable heterogeneity in HF disease burden, the resources available for its management and data quality across ESC member countries. The findings emphasize the need for a systematic approach to the capture of HF statistics so that inequalities and improvements in care may be quantified and addressed.
KW - Epidemiology
KW - HFA Atlas
KW - Heart failure
KW - Hospitalization
KW - Incidence
KW - Prevalence
UR - https://www.scopus.com/pages/publications/85111403758
U2 - 10.1002/ejhf.2143
DO - 10.1002/ejhf.2143
M3 - Article
C2 - 33634931
AN - SCOPUS:85111403758
SN - 1388-9842
VL - 23
SP - 906
EP - 914
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 6
ER -